Alternative polyadenylation site choice in proliferating cells emerges from a balance between RNA sequence signals, the concentration and activity of processing factors, and the transcriptional and chromatin environment. Proliferating cells frequently use proximal polyadenylation sites, producing mRNAs with shorter 3' untranslated regions that can escape microRNA regulation and increase protein output. Evidence for widespread 3' UTR shortening in proliferating and cancerous cells was described by Christine Mayr at Memorial Sloan Kettering Cancer Center and David P. Bartel at Whitehead Institute and Massachusetts Institute of Technology.
Sequence elements and core machinery
Cis-elements such as the canonical AAUAAA hexamer and its variants and downstream U or GU rich elements determine intrinsic site strength and recruit the core cleavage and polyadenylation complex. Bin Tian at University of Cincinnati College of Medicine and James L. Manley at Columbia University explain in a comprehensive review how CPSF, CstF and CFIm subunits recognize these signals and set site competence. Changes in the expression or assembly of these trans-acting factors shift competition among sites. For example, higher levels of cleavage stimulatory factors favor proximal site usage, while CFIm complexes tend to promote distal site choice, illustrating how relative factor abundance drives outcome.
Transcriptional dynamics, chromatin and cellular signaling
Transcriptional parameters and chromatin architecture modulate access to competing polyadenylation signals. RNA polymerase II elongation rate and promoter identity affect the temporal window for factor recruitment, and nucleosome positioning or histone modifications can expose or occlude downstream elements. Bin Tian and James L. Manley emphasize coupling between transcription, splicing and 3' end processing, and note that splicing factors and U1 small nuclear ribonucleoprotein can suppress premature cleavage at cryptic sites, making choice context-dependent.
Altered signaling in proliferating cells reshapes these determinants. Oncogenic or growth factor pathways can change expression of polyadenylation factors and splicing regulators, producing a selective advantage when 3' UTR shortening elevates oncogene expression as demonstrated by Christine Mayr and David P. Bartel. The result has human and territorial consequences: in immune activation, development and tumors across tissues, APA modulates protein dosage, subcellular localization and responsiveness to the microenvironment, affecting disease progression and potential therapeutic targeting.